Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials

By sjmartinez • February 11, 2023

Langley RG, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren RB, Paul C, Szepietowski JC, Tsai TF, Hampele I, You R, Charef P, Papavassilis C. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol. 2023 Feb 10;188(2):198-207. doi: 10.1093/bjd/ljac040. PMID: 36763857.

Tags: Dermatology, Publications

Primary Cutaneous Melanoma Microbiome is Associated with Overall Survival and Recurrence

Chan AA, Noguti J, Ramirez NM, Navarrete M, Lee DJ. Primary Cutaneous Melanoma Microbiome is Associated with Overall Survival and Recurrence. J Invest Dermatol. 2025[...]

To Treat or Not to Treat: Two Roads Traveled With Alopecia Areata

Taghizadeh CS, Goh C. To Treat or Not to Treat: Two Roads Traveled With Alopecia Areata. Pediatr Dermatol. 2025 Aug 15. doi: 10.1111/pde.70006. Epub ahead[...]

Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells

Li YR, Li Z, Zhu Y, Li M, Chen Y, Lee D, Ochoa CJ, Singh T, DiBernardo G, Guo W, Li S, Zhou Y, Yu[...]